- Home
- TDF vs FENC Comparison
TDF vs FENC Comparison
Compare TDF & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDF
- FENC
- Stock Information
- Founded
- TDF 1994
- FENC 1996
- Country
- TDF Singapore
- FENC United States
- Employees
- TDF N/A
- FENC N/A
- Industry
- TDF Finance/Investors Services
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TDF Finance
- FENC Health Care
- Exchange
- TDF Nasdaq
- FENC Nasdaq
- Market Cap
- TDF 244.7M
- FENC 225.4M
- IPO Year
- TDF N/A
- FENC 2001
- Fundamental
- Price
- TDF $11.12
- FENC $8.66
- Analyst Decision
- TDF
- FENC Strong Buy
- Analyst Count
- TDF 0
- FENC 2
- Target Price
- TDF N/A
- FENC $13.50
- AVG Volume (30 Days)
- TDF 79.2K
- FENC 58.9K
- Earning Date
- TDF 01-01-0001
- FENC 08-14-2025
- Dividend Yield
- TDF N/A
- FENC N/A
- EPS Growth
- TDF N/A
- FENC N/A
- EPS
- TDF N/A
- FENC N/A
- Revenue
- TDF N/A
- FENC $33,302,000.00
- Revenue This Year
- TDF N/A
- FENC $0.85
- Revenue Next Year
- TDF N/A
- FENC $55.16
- P/E Ratio
- TDF N/A
- FENC N/A
- Revenue Growth
- TDF N/A
- FENC N/A
- 52 Week Low
- TDF $7.15
- FENC $3.96
- 52 Week High
- TDF $10.62
- FENC $9.42
- Technical
- Relative Strength Index (RSI)
- TDF 74.54
- FENC 54.40
- Support Level
- TDF $10.55
- FENC $7.57
- Resistance Level
- TDF $10.70
- FENC $9.42
- Average True Range (ATR)
- TDF 0.16
- FENC 0.57
- MACD
- TDF 0.05
- FENC -0.01
- Stochastic Oscillator
- TDF 100.00
- FENC 66.22
About TDF Templeton Dragon Fund Inc.
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.